Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.
The neutrophil has been implicated as an important mediator of vascular injury, especially after endotoxemia. This study examines neutrophil-mediated injury to human microvascular endothelial cells in vitro. We found that neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine (FMLP), the complement fragment C5a, or lipopolysaccharide (LPS) (1-1,000 ng/ml) alone produced minimal endothelial injury over a 4-h assay. In contrast, neutrophils incubated with endothelial cells in the presence of low concentrations of LPS (1-10 ng/ml) could then be stimulated by FMLP or C5a to produce marked endothelial injury. Injury was maximal at concentrations of 100 ng/ml LPS and 10(-7) M FMLP. Pretreatment of neutrophils with LPS resulted in a similar degree of injury, suggesting that LPS effects were largely on the neutrophil. Endothelial cell injury produced by LPS-exposed, FMLP-stimulated neutrophils had a time course similar to that induced by the addition of purified human neutrophil elastase, and different from that induced by hydrogen peroxide (H2O2). Further, neutrophil-mediated injury was not inhibited by scavengers of a variety of oxygen radical species, and occurred with neutrophils from a patient with chronic granulomatous disease, which produced no H2O2. In contrast, the specific serine elastase inhibitor methoxy-succinyl-alanyl-alanyl-prolyl-valyl-chloromethyl ketone inhibited 63% of the neutrophil-mediated injury and 64% of the neutrophil elastase-induced injury. However, neutrophil-mediated injury was not inhibited significantly by 50% serum, 50% plasma, or purified alpha 1 proteinase inhibitor. These results suggest that, in this system, chemotactic factor-stimulated human neutrophil injury of microvascular endothelial cells is enhanced by small amounts of LPS and may be mediated in large part by the action of neutrophil elastase.
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D001769:Blood; D001798:Blood Proteins / Q000494:pharmacology; D003182:Complement C5 / Q000494:pharmacology; D015936:Complement C5a; D004727:Endothelium / Q000473:pathology*; D004731:Endotoxins / Q000494:pharmacology*; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000494:pharmacology; D008833:Microcirculation; D008854:Microscopy, Electron; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology*; D010196:Pancreatic Elastase / Q000378:metabolism*; D013997:Time Factors; D014107:Tosyllysine Chloromethyl Ketone / Q000494:pharmacology; D000515:alpha 1-Antitrypsin
D000590:Amino Acid Chloromethyl Ketones; D001798:Blood Proteins; D003182:Complement C5; D004731:Endotoxins; D008070:Lipopolysaccharides; D000515:alpha 1-Antitrypsin; D014107:Tosyllysine Chloromethyl Ketone; D009240:N-Formylmethionine Leucyl-Phenylalanine; C026704:methoxysuccinyl-alanyl-alanyl-prolyl-valine chloromethyl ketone; D015936:Complement C5a; D006861:Hydrogen Peroxide; D010196:Pancreatic Elastase